Xarelto Lawsuit Plaintiff Requests $4.35 Million Compensation For Alleged Internal Bleeding Episode

April 04, 2016 – – BloodThinnerHelp.com reports on the details of a lawsuit which was filed against defendants Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson), as well as several other defendants, in reference to new-generation blood thinner Xarelto. The plaintiff alleges that he is suing because he claims the anticoagulant drug caused him to experience a sudden and uncontrollable bleeding episode.

His lawsuit was transferred by the U.S. JPML to be consolidated with thousands of other federally-filed Xarelto lawsuits, forming multidistrict litigation number 2592 in Eastern Louisiana. All involved lawsuits, which now number over 2,800, are being overseen by The Honorable Judge Eldon Fallon, who has tentatively scheduled bellwether trial dates for early 2017.

Among the large number of Xarelto complaints, this one is especially significant as it involves 90-counts and a request by the plaintiff for $4.35 million in compensation. Details from lawsuit paperwork indicate that the plaintiff alleges defendants Bayer and Janssen misleadingly marketed Xarelto as a safe and effective medication for individuals looking to reduce their stroke risk. In addition, he alleges that the defendants neglected to sufficiently warn consumers of possibly dangerous or fatal side effects that he believes can be caused by the drug.

The plaintiff states that Janssen and Bayer may have been very aware that the blood thinner could cause an increased risk of the development of sudden bleeding episodes among patients taking it. He notes that clinical studies conducted on Xarelto help lend support to his argument, and claims that if the defendants had in fact been aware of these potential dangers, they acted with negligence by neglecting to protect the public by informing them of this critical product information. The plaintiff said, “Defendants use the results of the Rocket AF study, the Record studies, and the Einstein studies to promote Xarelto in their promotional materials, including the Xarelto website, which tout the positive results of those studies. However, defendants’ promotional materials fail to similarly highlight the increased risk of gastrointestinal bleeding and bleeding that required transfusion among other serious bleeding concerns.”

Xarelto gained approval by the U.S. Food and Drug Administration (FDA) in 2011. The drug was intended to treat patients with pulmonary embolism, and deep vein thrombosis as well as those recovering from hip and knee replacement surgeries, and this approval was later expanded to include treatment for patients with atrial fibrillation. Today, lawsuits filed in reference to the drug continue to increase in number, and have surpassed 3,400. Federally-filed Xarelto lawsuits have been transferred and consolidated to a single court in Eastern Louisiana by the U.S. Judicial Panel on Multidistrict Litigation, to form MDL number 2592. This MDL is now made up of more than 2,800 complaints filed against Xarelto manufacturers, while another group of over 620 other lawsuits has been consolidated to form a mass tort program by the Court of Common Pleas in Philadelphia, Pennsylvania.

Because filings are predicted to continue to increase in number, Attorney Joseph Osborne is working to assist others who have taken Xarelto and suffered from adverse events that they believe were caused by their use of the blood thinner. He hopes to help ensure that these patients will be given the important opportunity to fully explore their legal rights in the matter. Affected individuals could be entitled to substantial compensation. To assist those interested in further investigating their legal options, Attorney Osborne is currently offering free Xarelto consultations for qualified parties.

To request additional Xarelto lawsuit information, or to ask questions, contact Attorney Osborne by calling (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60009048